FrançaisNovacyt partners with Applied Microarrays US partnership to facilitate the design and optimisation for customised microarray assays
Visit PageNews and Events
Half Year Revenue Update Primerdesign revenues up 18% to €3m Strong pipeline of B2B and tender prospects Decision to undertake a strategic review of the NOVAprep® business
Trading update for six months to 30 June 18 Paris, France and Camberley, UK – 2 August 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited half year revenue update for the six months to 30 June 2018.
Visit PageNovacyt Announces Acquisition of Infectious Disease Business from Omega Diagnostics
Acquisition of ID business from Omega Diagnostics Accelerating profitability by expanding the Lab21 business with complimentary products
Visit Page